American Statistical Association
Pharmacogenomic biomarkers are a critical component of a targeted therapy as they can be used to identify patients who are most likely to benefit from a treatment. New study designs are required which can effectively evaluate both the diagnostic and the therapeutic intervention of pharmacogenomic biomarkers. We propose a Bayesian response adaptive design which utilizes individual pharmacogenomic profiles and patients' clinical outcomes as they became available during the course of the trial to assign the most effective treatment to individual patients. A series of simulation studies were conducted to examine the operating characteristics of the proposed study design. The simulation studies show that the proposed Bayesian response adaptive design identifies patients who benefit most from a targeted therapy and that there are substantial savings in the sample size requirements.
|Date:||Wednesday, April 8, 2009|
|Time:||4:00 - 5:00 P.M.|
Memorial Sloan-Kettering Cancer Center
Department of Epidemiology and Biostatistics
307 East 63rd Street
(between First and Second Avenues)
3rd Floor Conference Room
New York, New York
Note: To gain access to the building, please follow the directions by the telephone in the foyer.